MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$22K
Net Income
-$74,727K
Net Profit Margin
-339668.18%
EPS
-$0.94
Unit: Thousand (K) dollars
Revenue Breakdown
Grant
Service
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
22
15
120
-
Research and development
67,542
73,001
75,333
62,931
General and administrative
13,103
11,449
11,941
10,686
Total operating expenses
80,645
84,450
87,274
73,617
Operating loss
-80,623
-84,435
-87,154
-73,617
Investment and other income, net
7,120
5,750
5,837
6,573
Net loss
-73,503
-78,685
-81,317
-67,044
Unrealized (gain) loss on marketable securities
-1,224
-1,104
-139
426
Comprehensive loss
-74,727
-79,789
-81,456
-66,618
Basic EPS
-0.94
-1.18
-0.307
-1.01
Diluted EPS
-0.94
-1.18
-0.307
-1.01
Basic Average Shares
77,840,000
66,566,000
265,488,805
66,420
Diluted Average Shares
77,840,000
66,566,000
265,488,805
66,420
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$74,727K
(-31.49%↓ Y/Y)
Net loss
-$73,503K
(-29.86%↓ Y/Y)
Unrealized (gain) loss on
marketable securities
-$1,224K
(-434.50%↓ Y/Y)
Investment and other
income, net
$7,120K
(-1.89%↓ Y/Y)
Grant
$15K
(-97.93%↓ Y/Y)
Service
$7K
(0.00%↑ Y/Y)
Operating loss
-$80,623K
(-26.26%↓ Y/Y)
Total revenues
$22K
(-96.99%↓ Y/Y)
Total operating
expenses
$80,645K
(24.86%↑ Y/Y)
Research and development
$67,542K
(24.63%↑ Y/Y)
General and
administrative
$13,103K
(26.10%↑ Y/Y)
Buy us a coffee
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX)